The top 5 psychedelic clinical trials of 2022

Emerging Research
Written By

Psychedelic Alpha’s Medical Advisor, Michael Haichin, nominates what he felt were the five most impressive psychedelic clinical trials of 2022.  In no particular order, they were: *** Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. *** Lysergic Acid Diethylamide-Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II Study.  *** Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial. *** Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder … and … *** Exploratory investigation of a patient-informed low-dose psilocybin pulse regimen in the suppression of cluster headache: Results from a randomized, double-blind, placebo-controlled trial.  Each of these papers is introduced and helpfully discussed.  This review is well worth looking back at.

For more psychedelic news and research, visit the psychedelic health professional network homepage.

Previous

Psychedelic Therapies at the Crossroads of Trauma and Substance Use
Next

Dosing and therapeutic conduct in administration sessions in substance-assisted psychotherapy: A systematized review